N-(3-Fluorphenyl)-maleamsaeure | 6633-31-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-Fluorphenyl)-maleamsaeure
• 英文别名: (Z)-4-(3-fluoroanilino)-4-oxobut-2-enoic acid
• CAS: 6633-31-4
• 化学式: C₁₀H₈FNO₃
• 分子量: 209.177
• InChiKey: FJNNPZCSFCJFME-PLNGDYQASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(3-Fluorphenyl)-maleamsaeure 在 乙酸酐 作用下， 生成 1-(3-氟苯基)-1H-吡咯-2,5-二酮
  参考文献：
  名称：

  N-芳基琥珀酸，N-芳基琥珀酰亚胺，N-芳基马来酸和N-芳基马来酰亚胺的取代基化学位移。

  摘要：

  检查了一系列N-芳基琥珀酸，N-芳基琥珀酰亚胺，N-芳基马来酸和N-芳基马来酰亚胺的NMR光谱，以评估酰胺基和酰亚胺基对苯的氢和碳核化学位移的电子影响戒指。

  DOI：

  10.1002/mrc.2450
• 作为产物：
  描述：

  马来酸酐 、 3-氟苯胺 在 溶剂黄146 作用下， 反应 0.17h， 生成 N-(3-Fluorphenyl)-maleamsaeure
  参考文献：
  名称：

  DABCO催化的偶氮甲亚胺与N-芳基马来酰亚胺的[3 + 2]环加成反应：易于接近二氮稠合的杂环

  摘要：

  已经开发了DABCO与马来酰亚胺偶氮甲亚胺的[3 + 2]环加成反应。该方法可以以高水平的区域选择性和良好的收率有效地提供二氮稠合的四环杂环。

  DOI：

  10.1016/j.tetlet.2015.11.030

文献信息

• Synthesis and in Vitro Evaluation of N-Substituted Maleimide Derivatives as Selective Monoglyceride Lipase Inhibitors
  作者：Nicolas Matuszak、Giulio G. Muccioli、Geoffray Labar、Didier M. Lambert

  DOI：10.1021/jm900461w

  日期：2009.12.10

  action is quickly terminated via enzymatic hydrolysis catalyzed by monoglyceride lipase (MGL). Regulating its endogenous level could offer therapeutic opportunities; however, few selective MGL inhibitors have been described so far. Here, we describe the synthesis of N-substituted maleimides and their pharmacological evaluation on the recombinant human fatty acid amide hydrolase (FAAH) and on the purified

  内源性大麻素2-花生四烯酸甘油酯（2-AG）在许多生理过程中起着重要作用，其作用通过甘油单酯脂肪酶（MGL）催化的酶促水解迅速终止。调节其内源水平可以提供治疗机会；然而，到目前为止，几乎没有描述选择性的MGL抑制剂。在这里，我们描述了N-取代的马来酰亚胺的合成及其对重组人脂肪酸酰胺水解酶（FAAH）和纯化人MGL的药理评价。先前已经描述了一些N-芳基马来酰亚胺（萨里奥（SM）；萨洛（OM）；Nevalainen，T .；Poso，A。莱蒂宁（JT）；贾文恩（T. Jarvinen）Niemi，R.大鼠小脑膜中2-花生四烯酸甘油水解酶中巯基敏感位点的表征。化学 生物学 2005年，12，649-656），为MGL抑制剂，以及沿着这些线路，我们提出一组新的马来酰亚胺衍生物的那显示出低微摩尔的IC 50和朝向MGL VS FAAH高选择性。然后，研究了结构活性关系，例如，1-biphenyl-4
• Donya, A. P.; Pakter, M. K.; Sokhina, S. I., Russian Journal of Applied Chemistry, 1993, vol. 66, # 12.2, p. 2093 - 2097
  作者：Donya, A. P.、Pakter, M. K.、Sokhina, S. I.

  DOI：——

  日期：——
• Synthesis and biological evaluation of novel benzylidene-succinimide derivatives as noncytotoxic antiangiogenic inhibitors with anticolorectal cancer activity in vivo
  作者：Kaixiu Luo、Yafeng Bao、Feifei Liu、Chuanfan Xiao、Ke Li、Conghai Zhang、Rong Huang、Jun Lin、Jihong Zhang、Yi Jin

  DOI：10.1016/j.ejmech.2019.06.094

  日期：2019.10

  A novel series of benzylidene-succinimide derivatives were synthesized, characterized and evaluated for their cytotoxicities against HCT116, and SW480 cancer cells and NCM460 normal human cells. Their antiangiogenic capabilities were evaluated using a chick chorioallantoic membrane (CAM) assay. The compound, XCF-37b, was selected as the most potent antiangiogenic inhibitor with noncytotoxicity to evaluate the pharmacological effects on human umbilical vein endothelial cells (HUVECs) and cancer cells in vivo and in vitro. The results showed that XCF-37b inhibited HT29-cell colon tumor growth in vivo, without showing cytotoxicity against the five other cancer cell lines in vitro. Experiments confirmed that XCF-37b had obvious antiangiogenic activity by HUVEC migration and invasion and rat aortic ring angiogenesis ex vivo. Mechanism studies showed that XCF-37b inhibited the AKT/mTOR and VEGFR2 signaling pathways, as evidenced by decreased expressions of phosphor-AKT (p-AKT), p-mTOR, p-VEGFR2 (Tyr175), p-Src (Tyr416), p-FAK (Tyr925), and p-Erk1/2 (Thr202/Tyr204). Moreover, XCF-37b significantly decreased the protein expressions of matrix metalloproteinase-2 (MMP-2), MMP-9 and hypoxia-inducible factor-1 alpha (HIF-1 alpha). XCF-37b generally regulated angiogenic inhibition through several regulatory pathways, without significantly interfering with colorectal cancer cell growth. (C) 2019 Elsevier Masson SAS. All rights reserved.
• SALTS OF PAROXETINE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1091958A1

  公开（公告）日：2001-04-18
• [EN] SALTS OF PAROXETINE<br/>[FR] SELS DE PAROXETINE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO2000001692A1

  公开（公告）日：2000-01-13

  Piperidine compounds, processes for preparing them, pharmaceutical compositions comprising them and their use in therapy are disclosed.